These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 34357117)

  • 1. Personalized Medicine in Parkinson's Disease: New Options for Advanced Treatments.
    Mishima T; Fujioka S; Morishita T; Inoue T; Tsuboi Y
    J Pers Med; 2021 Jul; 11(7):. PubMed ID: 34357117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States.
    Amjad F; Bhatti D; Davis TL; Oguh O; Pahwa R; Kukreja P; Zamudio J; Metman LV
    Adv Ther; 2019 Sep; 36(9):2233-2246. PubMed ID: 31278691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalised Advanced Therapies in Parkinson's Disease: The Role of Non-Motor Symptoms Profile.
    Leta V; Dafsari HS; Sauerbier A; Metta V; Titova N; Timmermann L; Ashkan K; Samuel M; Pekkonen E; Odin P; Antonini A; Martinez-Martin P; Parry M; van Wamelen DJ; Ray Chaudhuri K
    J Pers Med; 2021 Aug; 11(8):. PubMed ID: 34442417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.
    Wirdefeldt K; Odin P; Nyholm D
    CNS Drugs; 2016 May; 30(5):381-404. PubMed ID: 27138916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update on advanced therapies for Parkinson's disease: From gene therapy to neuromodulation.
    Serva SN; Bernstein J; Thompson JA; Kern DS; Ojemann SG
    Front Surg; 2022; 9():863921. PubMed ID: 36211256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Application of levodopa/carbidopa intestinal gel in advanced Parkinson's disease].
    Toth A; Nagy H; Wacha J; Bereczki D; Takáts A
    Neuropsychopharmacol Hung; 2015 Dec; 17(4):191-6. PubMed ID: 26727723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of advanced therapies for Parkinson's disease in Norway.
    Ezat B; Pihlstrøm L; Aasly J; Tysnes OB; Egge A; Dietrichs E
    Tidsskr Nor Laegeforen; 2017 May; 137(9):619-623. PubMed ID: 28468476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Advanced Parkinson's disease : indication for complex treatments].
    Béreau M; Tomkova E; Zacharia A; Bouthour W; Fleury V; Bally JF; Horvath J; Momjian S; Lüscher C; Burkhard P; Krack P
    Rev Med Suisse; 2018 Apr; 14(604):875-878. PubMed ID: 29701432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parkinson's Disease: Personalized Pathway of Care for Device-Aided Therapies (DAT) and the Role of Continuous Objective Monitoring (COM) Using Wearable Sensors.
    Metta V; Batzu L; Leta V; Trivedi D; Powdleska A; Mridula KR; Kukle P; Goyal V; Borgohain R; Chung-Faye G; Chaudhuri KR
    J Pers Med; 2021 Jul; 11(7):. PubMed ID: 34357147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamics of device-based treatments for Parkinson's disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa-carbidopa intestinal gel, and deep brain stimulation.
    Richter D; Bartig D; Jost W; Jörges C; Stumpe B; Gold R; Krogias C; Tönges L
    J Neural Transm (Vienna); 2019 Jul; 126(7):879-888. PubMed ID: 31222604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Off-time Treatment Options for Parkinson's Disease.
    Fabbri M; Barbosa R; Rascol O
    Neurol Ther; 2023 Apr; 12(2):391-424. PubMed ID: 36633762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experience.
    Băjenaru O; Ene A; Popescu BO; Szász JA; Sabău M; Mureşan DF; Perju-Dumbrava L; Popescu CD; Constantinescu A; Buraga I; Simu M
    J Neural Transm (Vienna); 2016 Apr; 123(4):407-14. PubMed ID: 26699635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbidopa levodopa enteral suspension.
    Seeberger LC; Hauser RA
    Expert Opin Pharmacother; 2015; 16(18):2807-17. PubMed ID: 26595228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translating Evidence to Advanced Parkinson's Disease Patients: A Systematic Review and Meta-Analysis.
    Nijhuis FAP; Esselink R; de Bie RMA; Groenewoud H; Bloem BR; Post B; Meinders MJ
    Mov Disord; 2021 Jun; 36(6):1293-1307. PubMed ID: 33797786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced Parkinson's disease: clinical characteristics and treatment. Part II.
    Kulisevsky J; Luquin MR; Arbelo JM; Burguera JA; Carrillo F; Castro A; Chacón J; García-Ruiz PJ; Lezcano E; Mir P; Martinez-Castrillo JC; Martínez-Torres I; Puente V; Sesar A; Valldeoriola-Serra F; Yañez R
    Neurologia; 2013; 28(9):558-83. PubMed ID: 23880230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison Between Levodopa-Carbidopa Intestinal Gel Infusion and Subthalamic Nucleus Deep-Brain Stimulation for Advanced Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Liu XD; Bao Y; Liu GJ
    Front Neurol; 2019; 10():934. PubMed ID: 31507529
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment for advanced Parkinson's disease with intestinal levodopa/carbidopa gel: review of efficacy and safety].
    Timofeeva AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(11):145-51. PubMed ID: 25629138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous infusion of levodopa-carbidopa intestinal gel in Parkinson's disease.
    Guthikonda LN; Lyons KE; Pahwa R
    J Comp Eff Res; 2014 Jul; 3(4):331-3. PubMed ID: 25275230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?
    Catalán MJ; Antonini A; Calopa M; Băjenaru O; de Fábregues O; Mínguez-Castellanos A; Odin P; García-Moreno JM; Pedersen SW; Pirtošek Z; Kulisevsky J
    eNeurologicalSci; 2017 Sep; 8():44-53. PubMed ID: 29260038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
    Lowin J; Sail K; Baj R; Jalundhwala YJ; Marshall TS; Konwea H; Chaudhuri KR
    J Med Econ; 2017 Nov; 20(11):1207-1215. PubMed ID: 28895769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.